386 related articles for article (PubMed ID: 34769400)
1. Ciprofloxacin and Levofloxacin as Potential Drugs in Genitourinary Cancer Treatment-The Effect of Dose-Response on 2D and 3D Cell Cultures.
Kloskowski T; Szeliski K; Fekner Z; Rasmus M; Dąbrowski P; Wolska A; Siedlecka N; Adamowicz J; Drewa T; Pokrywczyńska M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769400
[TBL] [Abstract][Full Text] [Related]
2. Does ciprofloxacin have an obverse and a reverse?
Kloskowski T; Gurtowska N; Drewa T
Pulm Pharmacol Ther; 2010 Oct; 23(5):373-5. PubMed ID: 20211752
[TBL] [Abstract][Full Text] [Related]
3. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
4. New promising levofloxacin derivatives: Design, synthesis, cytotoxic activity screening, Topo2β polymerase inhibition assay, cell cycle apoptosis profile analysis.
El-Malah A; Youssef A; Ismail M; Kamel M; Mahmoud Z
Bioorg Chem; 2021 Aug; 113():105029. PubMed ID: 34091290
[TBL] [Abstract][Full Text] [Related]
5. Effect of four fluoroquinolones on the viability of bladder cancer cells in 2D and 3D cultures.
Kloskowski T; Fekner Z; Szeliski K; Paradowska M; Balcerczyk D; Rasmus M; Dąbrowski P; Kaźmierski Ł; Drewa T; Pokrywczyńska M
Front Oncol; 2023; 13():1222411. PubMed ID: 37534254
[TBL] [Abstract][Full Text] [Related]
6. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation.
Yadav V; Varshney P; Sultana S; Yadav J; Saini N
BMC Cancer; 2015 Aug; 15():581. PubMed ID: 26260159
[TBL] [Abstract][Full Text] [Related]
8. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC.
Kloskowski T; Gurtowska N; Olkowska J; Nowak JM; Adamowicz J; Tworkiewicz J; Dębski R; Grzanka A; Drewa T
Int J Oncol; 2012 Dec; 41(6):1943-9. PubMed ID: 23042104
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture.
Mondal ER; Das SK; Mukherjee P
Asian Pac J Cancer Prev; 2004; 5(2):196-204. PubMed ID: 15244525
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin exerts broad-spectrum anticancer activity via regulation of THBS1, LAPTM5, SRD5A3, MFAP5 and P4HA1.
He X; Yao Q; Hall DD; Song Z; Fan D; You Y; Lian W; Zhou Z; Duan L; Chen B
Anticancer Drugs; 2022 Jan; 33(1):e235-e246. PubMed ID: 34419964
[TBL] [Abstract][Full Text] [Related]
12. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
13. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates.
Hamasuna R; Ohnishi M; Matsumoto M; Okumura R; Unemo M; Matsumoto T
Microb Drug Resist; 2018; 24(1):30-34. PubMed ID: 28581359
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin criteria in antimicrobial prophylaxis and bladder cancer recurrence.
Gurtowska N; Kloskowski T; Drewa T
Med Sci Monit; 2010 Oct; 16(10):RA218-23. PubMed ID: 20885364
[TBL] [Abstract][Full Text] [Related]
16. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer.
Kamat AM; DeHaven JI; Lamm DL
Urology; 1999 Jul; 54(1):56-61. PubMed ID: 10414727
[TBL] [Abstract][Full Text] [Related]
17. Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa.
Zhao L; Wang S; Li X; He X; Jian L
Antimicrob Resist Infect Control; 2020 Aug; 9(1):124. PubMed ID: 32758289
[TBL] [Abstract][Full Text] [Related]
18. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
[TBL] [Abstract][Full Text] [Related]
19. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
[TBL] [Abstract][Full Text] [Related]
20. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
Grillon A; Schramm F; Kleinberg M; Jehl F
PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
